Comparative Pharmacology
Head-to-head clinical analysis: PRAZIQUANTEL versus VANSIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRAZIQUANTEL versus VANSIL.
PRAZIQUANTEL vs VANSIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Praziquantel increases the permeability of schistosome cell membranes to calcium ions, causing severe contraction and paralysis of the worm musculature, leading to dislodgment and death.
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
20 mg/kg orally three times daily for 1 day for schistosomiasis; 25 mg/kg orally three times daily for 1 day for clonorchiasis and opisthorchiasis; 5-10 mg/kg orally single dose for taeniasis; 15-25 mg/kg orally single dose for hymenolepiasis; 25 mg/kg orally three times daily for 1 day for paragonimiasis, fasciolopsiasis, and heterophyiasis.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
None Documented
None Documented
Clinical Note
moderatePraziquantel + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Cyclosporine
Terminal elimination half-life is 1-1.5 hours for praziquantel; 4-6 hours for its main metabolite (4-hydroxypraziquantel). Half-life prolonged in patients with severe hepatic impairment.
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Primarily renal: approximately 80% of metabolites excreted in urine (unchanged drug <0.1%); fecal excretion accounts for about 15%.
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Category A/B
Category C
Anthelmintic
Anthelmintic
"The metabolism of Cyclosporine can be decreased when combined with Praziquantel."